TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Telemonitoring Program on the Rate of Hospitalizations for Worsening of Cardio-respiratory Symptoms in COPD Patients Treated at Home by Long-term Non-invasive Ventilation (NIV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD~* Treated by long term NIV~* Compliance over 0h~* Hospitalized for worsening of cardio-respiratory symptoms at least once during the past year~* With social security coverage~Non inclusion Criteria:~* Evolutionary pathology (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing) (doctor's discretion)~* Patients whom referring general practitioner or pulmonologist is refusing to participate~* Person deprived of liberty~* Major protected by law~* Pregnant woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telemonitoring (Type: EXPERIMENTAL): Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
- control (Type: PLACEBO_COMPARATOR): Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.~Phone calls to patient during the follow-up like false alerts for the blind procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. On Dilantin for seizure prophylaxis (dose determined by primary caregiver) with therapeutic Dilantin levels~2. Receiving enteral nutrition by the interrupted method at goal feeding rate~3. Age \>18~4. Feeding tube in proper position, no restriction as to type of feeding tube (nasogastric, nasoduodenal, gastrostomy, jejunostomy), but both Dilantin and enteral feeding must be given through the same tube~Exclusion Criteria:~1. History of seizures~2. Albumin infusions necessary during study period~3. Anticipation that feedings will need to be held for more than 4 hours at a time~4. Patients that do not maintain stable Dilantin levels (\< 25% variability) with the interrupted method of feeding~5. Inability to obtain consent from patient or spokesperson

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe heart failure (NYHA grade III or IV)~* Chronic kidney disease stage 3-4~* Fluid overload resistant to diuretics OR hospital admission for HF in last 6 months~* Left ventricular ejection fraction ≤40% in last 2 years (moderate/severe)~* Using optimal HF medication for ≥ 4 weeks including ACE-inhibitor (angiotensin-converting-enzyme inhibitor) OR angiotensin receptor blocker AND aldosterone antagonist AND beta-blocker unless intolerant and without dose change for ≥ 4 weeks~* Appropriately screened for revascularization and/or cardiac resynchronization therapy if clinically indicated.~Exclusion Criteria:~* Does not wish to participate~* Mental incapacity to consent~* CKD stage 5~* Normal renal excretory function~* Haemodynamically significant valvular disease amenable to surgery~* Cardiac or renal transplantation~* Considered by the investigator to unsuitable for PD due to previous abdominal surgeries, peritonitis, social circumstances or other reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peritoneal Dialysis Group (Type: EXPERIMENTAL): These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
- Control Group (Type: NO_INTERVENTION): These participants will continue to receive standard HF care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years or older with histologically proven adenocarcinoma of the prostate~* Prior or current androgen deprivation for at least 6 months prior to study entry with either bilateral orchiectomy or being maintained on a stable dose of LHRH (luteinizing hormone-releasing hormone) agonist or antagonist~  * Hot flash frequency of an average of 2 or more per day (average of 14 hot flash episodes per week)~Exclusion Criteria:~* cannot currently be taking serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs)~  * cannot have uncontrolled hypertension~ * cannot have history of past or current of epilepsy, epilepsy syndrome or other seizure disorder~ * cannot have psychiatric history of mania, hypomania, bipolar disorder or anorexia nervosa~ * cannot be receiving concurrent treatment with amy medications or herbal products being used with the express purpose of treating hot flashes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Gabapentin (Type: EXPERIMENTAL): Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
- Arm B: Venlafaxine (Type: EXPERIMENTAL): Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The GlucoPred Investigation II

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diabetes mellitus type 1~* has read and understood the informed consent documentation and is willing to participate in the investigation and willing to sign the informed consent form~* willing to participate in the investigation using one or two GlucoPred sensors for a period of 8 days~* willing to attend 2 investigational visits with duration of up to 4 hours during the investigational period~* willing to take and record up to 16 finger-stick blood samples on Day 1 and up to 8 finger-stick blood samples daily for measuring reference values for the duration of the investigation~* Uses a blood-glucose monitoring system for self-testing on a daily basis~* Willing to use the provided blood-glucose monitoring system during the investigation~* Has access to and is willing to use a computer for downloading data and charging the sensor~Exclusion Criteria:~* not fit for the investigation due concurrent illness~* Unfit for participation for any reason judged by the investigator~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GlucoPred (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine in Postpartum Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent.~* Female patients with severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points~Exclusion Criteria:~* Woman with pre-existing psychotic disorder~* Patients with alcohol or substance abuse or dependence~* Patients who pose an imminent risk of suicide or danger to self or others

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine Fumarate 150 - 800mg (Type: EXPERIMENTAL): Quetiapine 150-800mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically documented invasive epithelial ovarian carcinoma, cancer of the fallopian tube or the peritoneum refractory to platinum-based chemotherapy or with partially platinum sensitive disease.~* Planned therapy with pegylated liposomal doxorubicin 50 mg/m² for recurrent platinum-refractory ovarian cancer.~* Patients with a progression-free-interval of 6 to 12 months after platinum-based chemotherapy are only eligible if a further course of platinum-based combination chemotherapy is not possible as judged by the investigator(s).~* Patients must have received at least one previous platinum- and taxane-based chemotherapy regimen.~Exclusion Criteria:~* Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days~* Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes or induce CYP3A4 function~* Treatment with mouse-antibodies in patients with evaluable disease and CA-125 progressive disease in the last 3 months. These patients are only eligible in case of measurable disease according to RECIST or cytological/histological proven relapse~* More than two prior lines of chemotherapy.~* Any chemotherapy or other systemic anti-cancer therapy within four weeks prior to randomization.~* Radiation therapy within the last 4 weeks prior to randomization (with the exception of palliative radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Vandetanib added to standard therapy (pegliposomal doxorubicin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DXR Stent(Previous Cilotax) Implantation Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with significant coronary artery disease and receiving Cilotax (dual drug eluting stent)~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site~Exclusion Criteria:~* Patients with a mixture of other DESs~* Terminal illness with life expectancy \<1 year~* Patients presented with cardiogenic shock

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Software Enhancements to the Respironics BiPAP autoSV Device Compared to BiPAP S/T Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-80.~* Ability to provide consent.~* Documentation of medical stability by investigator.~* Currently using BiPAP S/T (At least 4 weeks on therapy).~* Participants who previously demonstrated Complex Sleep Apnea (CSA), with a central apnea index (CAI) ≥5 during Diagnosis study or on Positive Airway Pressure (PAP) titration.~Exclusion Criteria:~* Participants, who are acutely ill, medically complicated or who are medically unstable.~* Participants in whom PAP therapy is otherwise medically contraindicated.~* Participants who are unwilling to wear PAP.~* Participants who are currently prescribed oxygen therapy.~* Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).~* Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.~* Participants with untreated, non-obstructive sleep apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome Periodic Limb Movement (PLM) Arousal Index \> 15).~* Participants who are unwilling to participate in the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Respironics BiPAP S/T (Type: ACTIVE_COMPARATOR): Control Arm using Respironics BiPAP S/T
- Respironics BiPAP Auto SV3 (Type: ACTIVE_COMPARATOR): Treatment arm using Respironics BiPAP Auto SV3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with isolated non-penetrating traumatic brain injury~* Multiple trauma patient with brain injury and traumas outside abdomen, thorax or pelvis not affecting oxygenation~* Glasgow coma scale eight or less (inclusive)~* Expected need for intubation and for mechanical ventilation more than 24 hours.~* Are recruited \<18 hours after admittance to ICU and~* Time from TBI is less than 36 hours~* Informed consent from patients representative~Exclusion Criteria:~* Age \<18 or \>65 years,~* Anticipated brain death in 12 hours (donor treatment) or otherwise moribund patient expected to die in 24 hours~* Expected need for mechanical ventilation less than 24 hours~* Insufficient oxygenation assessed by a clinician or multiple trauma patients with brain injury and severe abdominal, thoracic or pelvic injury possibly affecting oxygenation.~* No consent~* Insufficient oxygenation with the treatment modality of the lower oxygenation group (Pa02 less than 13 kPa or SpO2 95% with Fi02 40%, PEEP 10 or less) or oxygenation failure probable during ICU care (severe aspiration, multiple trauma patients with brain injury and severe abdominal, thoracic or pelvic injury possibly affecting oxygenation)~* Penetrating TBI~* No consent~* Suspected pregnancy (perform urinary or serological pregnancy test if suspected)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fraction of inspired oxygen of 0.4 (Type: ACTIVE_COMPARATOR): Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
- Fraction of inspired oxygen of 0.7 (Type: ACTIVE_COMPARATOR): Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Restriction in the Management of Cirrhotic Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cirrhotic patients of any etiology with ascites from portal hypertension diagnosed by paracentesis,~* Age 18-75~* Clinical or radiographic (abdominal CT or ultrasound) estimate of moderate - severe ascites~* Spanish-speaking subjects will be eligible for participation~Exclusion Criteria:~* Active drug or alcohol abuse,~* Active complications of SBP, hepatic encephalopathy, or GI bleed within 2 weeks,~* Hemorrhagic ascites, malignant ascites,~* Creatinine \>2 mg/dL or CCl \< 30 mL/min,~* K \> 5.5 mmol/L,~* Diuretic refractory ascites~* Allergy to or intolerance of either spironolactone or furosemide~* Homelessness, incarceration, inability to follow up in clinic, or comply with diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 4 gram sodium diet
- 2 (Type: ACTIVE_COMPARATOR): 2 gram sodium diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Triple A Initiative Study (Aktionsbündnis Akute Atemnot)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute dyspnea (NYHA II-IV)~* age \>= 18 years~* informed consent~Exclusion Criteria:~* cardiopulmonary resuscitation \< 7 days~* cardiogenic shock, STEMI, respiratory failure, or other clinical conditions that require immediate intensive care admission or angioplasty~* systolic blood pressure lower than 100 mmHg at first contact/presentation~* ventricular tachycardia~* severe aortic stenosis~* advanced neoplasm (e.g. lung cancer, hematologic neoplasm, etc.)~* chronic kidney disease requiring hemodialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- default group (Type: NO_INTERVENTION): Patients with the randomization result default group receive standard diagnostics
- POCT group (Type: ACTIVE_COMPARATOR): patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. history of overactive bladder~3. history of inadequate response to prior or current treatment with anti- muscarinic medication, or unacceptable side effects from higher dose of anti-muscarinic medication~4. PTNS-naive~5. willing to discontinue the use of anti-muscarinic agents for 2 weeks before start of study medication (washing out)~6. able to swallow and retain oral medication~7. able and willing to participate in the full duration of the study~8. able to read and write (health outcomes questionnaires are self-administered)and understand instructions related to study procedures and give written informed consent~9. OAB-q (items 1-8) score of 30 or higher~Exclusion Criteria:~1. presence of cardiac pacemaker and/or defibrillator~2. history of urinary retention~3. history of gastric retention~4. uncontrolled narrow angle glaucoma~5. any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction,coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 3 months prior to Screening visit~6. abnormal liver function test (greater than 3 times the upper limit of normal for alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or alkaline phosphatase \[ALP\]); or bilirubin \> 3 times the upper limit of normal~7. history of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject~8. known hypersensitivity to solifenacin~9. participation in any investigational or marketed drug trial within the 30 days prior to the first dose of study drug or any time during the study period~10. pregnancy or trying to become pregnant~11. breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTNS and solifenacin (Type: ACTIVE_COMPARATOR): PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
- PTNS and placebo (Type: PLACEBO_COMPARATOR): PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues